Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Awada A, Gil T, Whenham N, Van Hamme J, Besse-Hammer T, Brendel E, Delesen H, Joosten MC, Lathia CD, Loembé BA, Piccart-Ghebart M, Hendlisz A. Awada A, et al. Among authors: brendel e. J Clin Pharmacol. 2011 Dec;51(12):1674-84. doi: 10.1177/0091270010386226. Epub 2011 Jan 5. J Clin Pharmacol. 2011. PMID: 21209247 Clinical Trial.
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T. Awada A, et al. Among authors: brendel e. Eur J Cancer. 2012 Mar;48(4):465-74. doi: 10.1016/j.ejca.2011.12.026. Epub 2012 Jan 27. Eur J Cancer. 2012. PMID: 22285181 Clinical Trial.
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. Strumberg D, et al. Among authors: brendel e. J Clin Oncol. 2005 Feb 10;23(5):965-72. doi: 10.1200/JCO.2005.06.124. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613696 Clinical Trial.
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
Kupsch P, Henning BF, Passarge K, Richly H, Wiesemann K, Hilger RA, Scheulen ME, Christensen O, Brendel E, Schwartz B, Hofstra E, Voigtmann R, Seeber S, Strumberg D. Kupsch P, et al. Among authors: brendel e. Clin Colorectal Cancer. 2005 Sep;5(3):188-96. doi: 10.3816/ccc.2005.n.030. Clin Colorectal Cancer. 2005. PMID: 16197622 Clinical Trial.
A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors.
Mross K, Richly H, Schleucher N, Korfee S, Tewes M, Scheulen ME, Seeber S, Beinert T, Schweigert M, Sauer U, Unger C, Behringer D, Brendel E, Haase CG, Voliotis D, Strumberg D. Mross K, et al. Among authors: brendel e. Ann Oncol. 2004 Aug;15(8):1284-94. doi: 10.1093/annonc/mdh313. Ann Oncol. 2004. PMID: 15277271 Free article. Clinical Trial.
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
Richly H, Henning BF, Kupsch P, Passarge K, Grubert M, Hilger RA, Christensen O, Brendel E, Schwartz B, Ludwig M, Flashar C, Voigtmann R, Scheulen ME, Seeber S, Strumberg D. Richly H, et al. Among authors: brendel e. Ann Oncol. 2006 May;17(5):866-73. doi: 10.1093/annonc/mdl017. Epub 2006 Feb 24. Ann Oncol. 2006. PMID: 16500908 Free article. Clinical Trial.
63 results